211 related articles for article (PubMed ID: 17722509)
1. Nanomedicines in renal transplant rejection--focus on sirolimus.
Shen LJ; Wu FL
Int J Nanomedicine; 2007; 2(1):25-32. PubMed ID: 17722509
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection.
Mathew TH; Van Buren C; Kahan BD; Butt K; Hariharan S; Zimmerman JJ
J Clin Pharmacol; 2006 Jan; 46(1):76-87. PubMed ID: 16397287
[TBL] [Abstract][Full Text] [Related]
3. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
Liu JY; Song M; Guo M; Huang F; Ma BJ; Zhu L; Xu G; Li J; You RX
Am J Ther; 2016; 23(6):e1720-e1728. PubMed ID: 25569597
[TBL] [Abstract][Full Text] [Related]
6. Considerations in sirolimus use in the early and late post-transplant periods.
Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies.
Haeri A; Osouli M; Bayat F; Alavi S; Dadashzadeh S
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):1-14. PubMed ID: 29186990
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus solid self-microemulsifying pellets: formulation development, characterization and bioavailability evaluation.
Hu X; Lin C; Chen D; Zhang J; Liu Z; Wu W; Song H
Int J Pharm; 2012 Nov; 438(1-2):123-33. PubMed ID: 22850296
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method.
Solymosi T; Angi R; Basa-Dénes O; Ránky S; Ötvös Z; Glavinas H; Filipcsei G; Heltovics G
Eur J Pharm Biopharm; 2015 Aug; 94():135-40. PubMed ID: 26003815
[TBL] [Abstract][Full Text] [Related]
10. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
Kovarik JM
Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
[TBL] [Abstract][Full Text] [Related]
11. Individualizing early use of sirolimus in renal transplantation.
Rial Mdel C; Abbud-Filho M; Gonçalves RT; Martinez-Mier G; Montero C; Raffaele P; Toledo Solares M; Alberú J
Transplant Proc; 2010 Dec; 42(10):4518-25. PubMed ID: 21168728
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety.
Velosa JA; Larson TS; Gloor JM; Stegall MD
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S3-S10. PubMed ID: 11583938
[TBL] [Abstract][Full Text] [Related]
13. Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients.
Kelly PA; Napoli K; Kahan BD
Biopharm Drug Dispos; 1999 Jul; 20(5):249-53. PubMed ID: 10594869
[TBL] [Abstract][Full Text] [Related]
14. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
15. A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk.
Lee J; Lee JJ; Kim BS; Lee JG; Huh KH; Park Y; Kim YS
J Korean Med Sci; 2015 Jun; 30(6):682-7. PubMed ID: 26028917
[TBL] [Abstract][Full Text] [Related]
16. Everolimus: an immunosuppressive agent in transplantation.
Patel JK; Kobashigawa JA
Expert Opin Pharmacother; 2006 Jul; 7(10):1347-55. PubMed ID: 16805720
[TBL] [Abstract][Full Text] [Related]
17. Use of remote film loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for treatment of restenosis.
Haeri A; Sadeghian S; Rabbani S; Anvari MS; Boroumand MA; Dadashzadeh S
Int J Pharm; 2011 Jul; 414(1-2):16-27. PubMed ID: 21554939
[TBL] [Abstract][Full Text] [Related]
18. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
Lo A; Egidi MF; Gaber LW; Shokouh-Amiri MH; Nazakatgoo N; Fisher JS; Gaber AO
Clin Transplant; 2004 Feb; 18(1):53-61. PubMed ID: 15108771
[TBL] [Abstract][Full Text] [Related]
19. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus.
Miles CD; Skorupa JY; Sandoz JP; Rigley TH; Nielsen KJ; Stevens RB
Clin Transplant; 2011; 25(6):898-904. PubMed ID: 21077952
[TBL] [Abstract][Full Text] [Related]
20. Rapamune. New tablet combats kidney rejection.
Nursing; 2002 Apr; 32(4):26. PubMed ID: 11969008
[No Abstract] [Full Text] [Related]
[Next] [New Search]
